Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Benzinga · 1d ago
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.